Remove category matts-take
article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. In its third-quarter update, the Danish drugmaker reported sales of Rybelsus reached DKK 7.25

Drugs 52
article thumbnail

Coronavirus: UK case rises are 'concerning', says minister

The Pharma Data

At the peak of the virus in spring official figures showed there were 6,000 cases a day, although testing was largely only taking place in hospitals. Of course the people in those age categories are unlikely to become extremely unwell as a result of having the virus. “We have to keep hammering the message home.